Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Carvana Co (CVNA) vs Twist Bioscience Corp (TWST) Price & Performance

Carvana CoTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Carvana Co vs Twist Bioscience Corp — how do they compare? Carvana Co trades at $63.02 (market cap $69.55B), while Twist Bioscience Corp trades at $165.44 (market cap $10.08B). The key difference: Carvana Co is far larger — about 6.9× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Twist Bioscience Corp for 27 Days on average.

CVNATWST
Market Cap
$69.55B$10.08B
Volume
7,671,7504,229,037
Sector
Consumer CyclicalHealth
52-Week High
$95.69$205.00
52-Week Low
$56.27$25.45
Typical Hold Time
28 Days27 Days
Enterprise Value
$72.04B$10.01B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Carvana Co

Carvana (CVNA) trades at $62.76, down 1.72% with bearish technical signals but strong fundamental momentum. The stock shows impressive revenue growth from $13.7B in 2024 to $20.3B in 2025, with net income surging to $1.4B. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.42 exceeding the $0.39 forecast. Analyst sentiment remains divided with a $84.07 consensus target, though technical indicators show selling pressure with bearish moving averages and key resistance at $64.

Carvana presents a compelling growth story with expanding profitability and operational efficiency, though high valuation multiples and significant debt levels warrant caution. The company's aggressive capacity expansion addresses demand constraints, positioning it for continued market share gains in online auto retail. However, competitive pressures and macroeconomic sensitivity to interest rates remain key risks for investors.

Twist Bioscience Corp

TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.

The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CVNA
26% Buy74% Sell
Avg holding period · 28 Days
TWST
37% Buy63% Sell
Avg holding period · 27 Days

Top news

Latest headlines on both assets

About Carvana Co

Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.

Read more on CVNA →

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST →